STIM1 and metastatic malignant neoplasm in the lymph nodes: In summary, 66.7% (4/6) of mice in the shRNA-Ctrl group developed inguinal lymph node metastasis, whereas 0% (0/6) in the shRNA-STIM1 group developed lymph node metastasis (Figure 3E).